Latest News

Latest News

NICE publishes guidance for NHS England & Wales use of ofatumumab in combination with chlorambucil or bendamustine for untreated chronic lymphocytic leukaemia

Technology appraisal guidance [TA344] Published today June 2015
You can access full guidance details on the NICE website here:http://www.nice.org.uk/guidance/ta344

Ofatumumab (Arzerra) given with a drug called chlorambucil is recommended as a possible treatment for people with untreated chronic lymphocytic leukaemia if treatments containing fludarabine or bendamustine are not suitable.

What does this mean for me?

Idelalisib gains SMC approval for NHS Scotland use + early access programme

Idelalisib (Zydelig) has been accepted for restricted use by NHS Scotland. you can read more & access the full guidance PDF from the download on the SMC website.  

CLLSA have participated in the consultation process,  it is rewarding to see this now gain approval.  

SMC intitial guidance details:

following a full submission

Ofatumumab plus Chlorambucil and Obinutuzimab plus Chlorambucil Gain NICE preliminary approval for NHS treatment of CLL

CLLSA at NICE and preliminary NICE guidance for two new CLL treatments.

The CLLSA regulatory appraisals volunteer group are participating in six NICE consultations. CLLSA representatives commented on the following NICE documents and attended the Scope, Appraisal workshops and participated on appraisal committees to date this year this has resulted in the excellent news that two new treatments have already received preliminary recommendation by NICE for NHS treatment of CLL in England and Wales: